Literature DB >> 7363534

The pharmacokinetics of metoprolol and its metabolites in dialysis patients.

K U Seiler, K J Schuster, G J Meyer, W Niedermayer, O Wassermann.   

Abstract

The kinetics of tritiated metoprolol and its metabolites have been determined after intravenous and oral administration in dialysis patients. The kinetic behaviour of metoprolol in these patients does not differ from that in healthy volunteers, since its elimination depends on hepatic metabolism. The pharmacologically less active metabolite alpha-hydroxymetoprolol is formed to an individually varying degree and its half-life is prolonged. The concentration of the total radioactivity, which represents the sum of all metabolites, does not decline in the dialysis interval. During haemodialysis, however, its concentration decreases with a half-life of 5h. It might be assumed, that dialysis of these polar compounds is rather nonspecific and that it depends essentially on the dialysis technique.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7363534     DOI: 10.2165/00003088-198005020-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  5 in total

1.  Tissue distribution of metoprolol-(3-h) in the mouse and the rat.

Authors:  N O Bodin; K O Borg; R Johnansson; C H Ramsay; I Skänberg
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Metabolism of metoprolol-(3-h) in man, the dog and the rat.

Authors:  K O Borg; E Carlsson; K J Hoffmann; T E Jönsson; H Thorin; B Wallin
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

3.  The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.

Authors:  K J Hoffmann; C G Regårdh; M Aurell; M Ervik; L Jordö
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

4.  Selected ion monitoring of metoprolol and two metabolites in plasma and urine using deuterated internal standards.

Authors:  M Ervik; K J Hoffmann; K Kylberg-Hanssen
Journal:  Biomed Mass Spectrom       Date:  1981-07

5.  Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.

Authors:  L Jordö; P O Attman; M Aurell; L Johansson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

  5 in total
  12 in total

1.  β-Blocker dialyzability and mortality in older patients receiving hemodialysis.

Authors:  Matthew A Weir; Stephanie N Dixon; Jamie L Fleet; Matthew A Roberts; Daniel G Hackam; Matthew J Oliver; Rita S Suri; Robert R Quinn; Sundus Ozair; Michael M Beyea; Abhijat Kitchlu; Amit X Garg
Journal:  J Am Soc Nephrol       Date:  2014-10-30       Impact factor: 10.121

2.  β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.

Authors:  Alvin Tieu; Thomas J Velenosi; Andrew S Kucey; Matthew A Weir; Bradley L Urquhart
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-08       Impact factor: 8.237

Review 3.  Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol.

Authors:  M J Kendall
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 4.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

5.  The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.

Authors:  K J Hoffmann; C G Regårdh; M Aurell; M Ervik; L Jordö
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

Review 6.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 7.  The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.

Authors:  S Nattel; G Gagne; M Pineau
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

8.  Pharmacokinetics of mepindolol in patients with chronic renal failure.

Authors:  W Krause; D Kampf; H C Fischer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.

Authors:  L Jordö; P O Attman; M Aurell; L Johansson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

10.  Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

Authors:  J Fabre; H M Fox; P Dayer; L Balant
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.